X0306 4 2023-01-26 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001509688 Schorno Dean L RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true EVP & Chief Financial Officer Common Stock 2023-01-26 4 A 0 63000 0 A 201908 D Employee Stock Option (right to buy) 2.42 2023-01-26 4 A 0 50000 0 A 2032-01-24 Common Stock 50000 100000 D Employee Stock Option (right to buy) 1.87 2023-01-26 4 A 0 125000 0 A 2033-01-26 Common Stock 125000 125000 D The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024. Includes 10,000 shares acquired under the issuer's stock purchase plan. The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met. The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met. The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period. /s/ Raymond Furey (Attorney-in-Fact) 2023-01-30